Internal Medicine, Hematology & Oncology · Trenton, NJ
NPI
1396947503
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
40 Fuld St Ste 404
Trenton, NJ, 08638
Phone (609) 394-0660
Groups this clinician bills Medicare through
Medicare paid, 2024
$80K
3,209 services
Medicare patients, 2024
255
Average age 73
Drug cost, 2024
$3.7M
1,406 prescriptions
Company payments, 2025
$1,254
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Emily Q Chen was code 99214 (office e&m - established), 167 times for 99 patients. In total Emily Q Chen billed 3,209 services in 19 codes, and Medicare paid $80K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 167 | 99 | $100.50 | $17K |
| 96372 Injection Administration | Office | 114 | 17 | $12.86 | $1,466 |
| 99215 Office E&M - Established | Office | 84 | 50 | $161.68 | $14K |
| 99213 Office E&M - Established | Office | 82 | 51 | $66.64 | $5,464 |
| 99232 Hospital E&M - Subsequent | Facility | 73 | 41 | $69.92 | $5,104 |
| 36415 Venipuncture Blood Collection | Office | 69 | 47 | $8.52 | $588 |
| 99223 Hospital E&M - Initial | Facility | 62 | 62 | $151.21 | $9,375 |
| 99233 Hospital E&M - Subsequent | Facility | 52 | 36 | $103.14 | $5,363 |
| 99205 Office E&M - New | Office | 25 | 25 | $183.78 | $4,595 |
| 99204 Office E&M - New | Office | 15 | 15 | $131.91 | $1,979 |
By year: 2022 $86K for 2,906 services; 2023 $70K for 2,378 services; 2024 $80K for 3,209 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 69 | 47 | $8.52 | $588 |
Medicare prescription drug claims, 2024
In 2024, the drug Emily Q Chen prescribed most often to Medicare patients was Eliquis (Apixaban), with 252 prescriptions and refills. In total Emily Q Chen wrote 1,406 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 252 | 358 | 42 | $204K |
| Oxycodone Hcl Generic | 79 | 79 | 24 | $1,541 |
| Xarelto Rivaroxaban | 60 | 76 | 11 | $42K |
| Hydroxyurea Generic | 57 | 113 | 14 | $1,308 |
| Letrozole Generic | 50 | 68 | Under 11 | $758 |
| Anastrozole Generic | 50 | 94 | Under 11 | $831 |
| Lenalidomide Generic | 48 | 48 | Under 11 | $640K |
| Revlimid Lenalidomide | 39 | 39 | Under 11 | $651K |
| Prednisone Generic | 38 | 39 | Under 11 | $203 |
| Ondansetron Odt Ondansetron | 35 | 35 | 17 | $654 |
| Dexamethasone Generic | 34 | 40 | 12 | $593 |
| Amlodipine Besylate Generic | 29 | 48 | Under 11 | $130 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 25 | 25 | 11 | $632 |
| Warfarin Sodium Generic | 24 | 61 | Under 11 | $354 |
| Deferasirox Generic | 23 | 23 | Under 11 | $12K |
Brand drugs: 497 claims; generic drugs: 909 claims; opioid claims: 164.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Emily Q Chen $1,254 ($1,254 in general payments such as food, travel and fees) from 27 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $160.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 8 | $160 |
| Daiichi Sankyo Inc. 4568.T | 3 | $159 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $142 |
| Eisai Inc. 4523.T | 4 | $91.9 |
| Astellas Pharma US Inc 4503.T | 4 | $66.04 |
| Pfizer Inc. PFE | 3 | $56.76 |
| ALK-Abello, Inc | 3 | $52.87 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $52.86 |
| Gilead Sciences, Inc. GILD | 3 | $48.95 |
| Janssen Biotech, Inc. JNJ | 2 | $40.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.